Table 1. Characteristics of the study population.
| Variable | Patients included (n=123) | Patients excluded (n=108)* | p-value† | |
|---|---|---|---|---|
| Age (yr)‡ | 61.3 (52.1-68.5) | 61.4 (51.1-70.1) | 0.950 | |
| Histology | 0.030 | |||
| Serous | 83 (67.5%) | 64 (59.3%) | ||
| Mucinous | 9 (7.3%) | 7 (6.5%) | ||
| Endometrioid | 9 (7.3%) | 10 (9.2%) | ||
| Clear cell | 5 (4.1%) | 6 (5.6%) | ||
| Adenocarcinoma NOS | 13 (10.6%) | 10 (9.2%) | ||
| Carcinosarcoma | 3 (2.4%) | 9 (0%) | ||
| Other | 1 (0.8%) | 11 (10.2%) | ||
| Tumor grade | 0.280 | |||
| 1 | 7 (5.7%) | 11 (10.2%) | ||
| 2 | 26 (21.2%) | 25 (23.1%) | ||
| 3 | 65 (52.8%) | 47 (43.5%) | ||
| Unknown | 25 (20.3%) | 25 (23.2%) | ||
| FIGO stage | 0.050 | |||
| II | 10 (8.1%) | 19 (17.6%) | ||
| III | 89 (72.4%) | 76 (70.4%) | ||
| IV | 24 (19.5%) | 13 (12.0%) | ||
| Ascites | 0.010 | |||
| None | 34 (27.6%) | 13 (12.0%) | ||
| 0–1,000 mL | 27 (22.0%) | 35 (32.4%) | ||
| >1,000 mL | 51 (41.5%) | 45 (41.7%) | ||
| Unknown | 11 (8.9%) | 15 (13.9%) | ||
| Residual tumor size after debulking | 0.320 | |||
| Complete | 33 (26.8%) | 37 (34.2%) | ||
| Optimal | 47 (38.2%) | 42 (38.9%) | ||
| Suboptimal | 43 (35.0%) | 29 (26.9%) | ||
| Extensive surgery | 0.030 | |||
| Yes | 48 (39.0%) | 28 (25.9%) | ||
| No | 75 (61.0%) | 80 (74.1%) | ||
| CA125, U/mL | ||||
| Preoperative | 650 (504–837) | |||
| Postoperative | 197 (159–243) | |||
| Perioperative decline | 427 (310–588) | |||
| Follow-up time (mo)§ | 31 (18–49) | |||
FIGO, International Federation of Gynecology and Obstetrics.
*Excluded due to a lack of data regarding CA125 levels; †Unpaired t test (age) and χ2 test (other characteristics); ‡Mean (interquartile range); §Geometric means (95% confidence interval).